<DOC>
	<DOCNO>NCT02474303</DOCNO>
	<brief_summary>Recent breakthrough antiretroviral ( ARV ) -based prevention provide new opportunity rethink HIV prevention treatment strategy , especially key population Female Sex Workers ( FSWs ) . Antiretroviral ( ARV ) -based prevention HIV transmission potential profound population-level impact course HIV/AIDS pandemic . Several recently complete randomize control trial HIV Pre-exposure Prophylaxis ( PrEP ) show efficacy reduce HIV acquisition high-risk population . How translate trial result population-level effect next critical step . PrEP `` demonstration '' project , collaboration local stakeholder sit routine care high-risk population provide opportunity move promise research result actual public health benefit . With key feature mind , investigator propose HIV PrEP demonstration project FSW Dakar , Senegal , West Africa . The objective propose demonstration project Tenofovir DF/Emtricitabine ( TDF/FTC ) among Female Sex Workers ( FSW ) Dakar Senegal build sustainable HIV PrEP program FSW Dakar , Senegal demonstrate feasibility provide daily oral PrEP Truvada ( TDF/FTC ) 12 month enrol FSW Ministry Heath run clinic ( IHS , Pikine , Mbao , Rufisque Diamniadio Health Centers ) . Critical milestone demonstration project feasibility , uptake , acceptability , use TDF/FTC PrEP programmatic retention FSWs Dakar MoH clinic . The investigator assemble expert team RARS , The University Washington , Westat great 2 decade collaboration HIV related project FSWs Senegal . The investigator expect result project show Senegal provide unique opportunity ass acceptability , feasibility , uptake effectiveness oral HIV PrEP reduce HIV transmission high-risk FSW population .</brief_summary>
	<brief_title>Demonstration Project PrEP Among Female Sex Workers Dakar , Senegal</brief_title>
	<detailed_description>STUDY DESIGN This two-phase study , consist follow : PHASE I - The feasibility evaluation study take several form . - Observations - Field-based assessment service delivery five site ; - In-depth interview - With policy maker , program manager , service provider , well community member leader ; - Focus group register unregistered female sex worker ( FSW ) . PHASE II - This prospective demonstration study oral pre-exposure prophylaxis ( PrEP ) Emtricitabine/Tenofovir Disoproxil Fumarate ( FTC/TDF ) FSW 12 month follow 3-month accrual period . A total 1500 FSW enrol . OBJECTIVES Primary Objectives : - Build sustainable HIV PrEP program FSW Dakar , Senegal . - Demonstrate feasibility provide daily oral PrEP FTC/TDF 12 month FSW Ministry Health ( MoH ) -run clinic ( Institut d'Hygiène Sociale ( IHS ) , Pikine , Mbao , Rufisque Diamniadio Health Centers ) Dakar . POPULATION &amp; SAMPLE SIZE PHASE I : - 10 Key Informants : Policy maker , program manager , service provider , well community member leader . - Focus Group Participants : 8 Registered 8 Unregistered HIV-negative FSW age 18 older . PHASE II : • 1500 HIV-negative FSW age 18 older recruit five public health center Dakar : IHS , Pikine , Mbao , Rufisque Diamniadio Health Centers . PROTOCOL EVALUATIONS - PHASE I : Qualitative data observation , key informant interview , focus group collect , analyze use inform implementation Phase II . - PHASE II : Quantitative data collect use behavioral measure clinical laboratory evaluation . Data electronic monitoring also collect . STUDY DURATION 24 month REGIMEN Daily oral PrEP FTC/TDF 12 month</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>• Completion write informed consent process prior undergo screen evaluation ≥ 18 year older Active sex work ( Paid sex within past six month ) In general good health , confirm medical history physical examination Has laboratory evidence absence HIV infection , define negative 4th generation HIV ELISA test prior enrollment Serum creatinine less equal upper limit normal ( ULN ) calculate creatinine clearance least 70 mL/minute CockcroftGault formula Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 2.5 time ULN Hemoglobin great 8.5 g/dL Does report intention relocate study area course study If able become pregnant , selfreported use effective method contraception enrollment , intend use effective method followup period Without sign symptom acute HIV infection ( acute retroviral syndrome ) • HIV1 HIV2 screen test reactive Is enrolled clinical product trial Serious active medical condition Proteinuria 2+ great screen Glucosuria 2+ great screening Use disallow medication ( *See note ) Presence active serious psychiatric symptom ( e.g. , active hallucination , suicidal , homicidal , exhibit violent behavior ) time consent Intoxicated influence alcohol drug time screen Pregnant female female breastfeed Any reason condition opinion investigator would interfere participation , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Truvada</keyword>
	<keyword>EMTRICITABINE/TENOFOVIR DISPROXIL FUMARATE</keyword>
	<keyword>HIV PREEXPOSURE PROPHYLAXIS ( PrEP )</keyword>
	<keyword>Female Sex Workers</keyword>
</DOC>